Skip to Main Content

Paper Details

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Nat Commun
48
2020
BRAF, BRAF-mutated melanoma, BRAF-wild type melanoma, MAPK, MEK, PD-L1, advanced melanoma, dabrafenib, durvalumab, oncogenic mitogen-activated protein kinase, patients, trametinib, tumor
Author NameAffiliation
Antoni RibasUniversity of California Los Angeles (university of california los angeles) and Jonsson Comprehensive Cancer Center at university of california los angeles
Antoni RibasUniversity of California Los Angeles (university of california los angeles) and Jonsson Comprehensive Cancer Center at university of california los angeles
Katie M CampbellUniversity of California Los Angeles (university of california los angeles) and Jonsson Comprehensive Cancer Center at university of california los angeles
Caroline RobertGustave Roussy Cancer Campus and Paris-Saclay University
  • 1 - 4

Datasets

Release 1.2